{"id":29413,"date":"2014-08-25T10:21:52","date_gmt":"2014-08-25T14:21:52","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=29413"},"modified":"2014-08-25T10:21:52","modified_gmt":"2014-08-25T14:21:52","slug":"alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413","title":{"rendered":"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Declared Initiation Of Eculizumab (Soliris\u00ae) Trial For Delayed Graft Function Prevention After Kidney Transplantation"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 08\/25\/2014 (wallstreetpr) \u2013 <strong>Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)<\/strong> announced today that it will be starting clinical trial of <a href=\"http:\/\/finance.yahoo.com\/news\/alexion-initiates-multinational-registration-trial-103000404.html\"><strong>eculizumab (Soliris<sup>\u00ae<\/sup>)<\/strong><\/a> in order to evaluate its safety and efficiency. The clinical trial shall be placebo-controlled, single and multinational. This clinical trial shall be carried out for preventing delayed graft function (DGF) among kidney patients.<\/p>\n<p style=\"text-align: justify;\"><strong>What is delayed graft function (DGF)?<\/strong><\/p>\n<p style=\"text-align: justify;\">DGF is found to affect around 25% and as many as 50% deceased-donor kidney transplant cases. This is a serious complication and also early one. DGF is primarily indicative with the failure of transplanted organ, immediately after transplantation. Patients who suffer from DGF need immediate dialysis even after kidney transplant.<\/p>\n<p style=\"text-align: justify;\"><strong>Need for Treating DGF Immediately<\/strong><\/p>\n<p style=\"text-align: justify;\">The clinical trials are meant to address DGF condition as there is an increased medical need to cater to patients suffering from DGF. As of now, no treatment for this condition has been approved yet.<\/p>\n<p style=\"text-align: justify;\"><strong>Statement from Alexion Pharmaceuticals<\/strong><\/p>\n<p style=\"text-align: justify;\">The executive vice president and global head at R&amp;D Department of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), <em>Martin Mackay<\/em>, Ph.D. said that Delayed graft function is a serious complication which arises after successful kidney transplantation. This, he added, is life threatening because of loss of transplanted organ.<\/p>\n<p style=\"text-align: justify;\">Complement activation has a crucial role to play in development of DGF. Martin Mackay also said that because of shortage of donor organs, it becomes important to reduce the risk of DGF so as to also bring down the waiting time for receiving transplant.<\/p>\n<p style=\"text-align: justify;\"><strong>Eculizumab (Soliris<sup>\u00ae<\/sup>) Approval Status<\/strong><\/p>\n<p style=\"text-align: justify;\">Soliris, at present, has been approved in around 50 countries for paroxysmal nocturnal hemoglobinuria (PNH) patients. Also, 40 countries have approved Soliris for atypical hemolytic uremic syndrome (aHUS) treatment along with two ultra-rare, debilitating and critically fatal disorders which can be caused because of chronic uncontrolled complement activation. However, it is important to note, no country in the world, as yet given its approval to Soliris for preventing DGF after kidney transplant. Approval of Soliris will therefore be a great achievement for the company.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 08\/25\/2014 (wallstreetpr) \u2013 Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that it will be starting clinical trial of eculizumab (Soliris\u00ae) in order to evaluate [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":29414,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[8348,3735],"stock_ticker":[],"class_list":["post-29413","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-alexion-pharmaceuticals-inc-nasdaqalxn","tag-nasdaqalxn","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Declared Initiation Of Eculizumab (Soliris\u00ae) Trial For Delayed Graft Function Prevention After Kidney Transplantation - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Declared Initiation Of Eculizumab (Soliris\u00ae) Trial For Delayed Graft Function Prevention After Kidney Transplantation - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 08\/25\/2014 (wallstreetpr) \u2013 Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that it will be starting clinical trial of eculizumab (Soliris\u00ae) in order to evaluate [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-08-25T14:21:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Alexion-Pharmaceuticals-Inc.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"259\" \/>\n\t<meta property=\"og:image:height\" content=\"194\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Brendan Byrne\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Brendan Byrne\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413\"},\"author\":{\"name\":\"Brendan Byrne\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\"},\"headline\":\"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Declared Initiation Of Eculizumab (Soliris\u00ae) Trial For Delayed Graft Function Prevention After Kidney Transplantation\",\"datePublished\":\"2014-08-25T14:21:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413\"},\"wordCount\":349,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Alexion-Pharmaceuticals-Inc.jpg\",\"keywords\":[\"Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)\",\"NASDAQ:ALXN\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413\",\"name\":\"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Declared Initiation Of Eculizumab (Soliris\u00ae) Trial For Delayed Graft Function Prevention After Kidney Transplantation - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Alexion-Pharmaceuticals-Inc.jpg\",\"datePublished\":\"2014-08-25T14:21:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Alexion-Pharmaceuticals-Inc.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Alexion-Pharmaceuticals-Inc.jpg\",\"width\":259,\"height\":194},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Declared Initiation Of Eculizumab (Soliris\u00ae) Trial For Delayed Graft Function Prevention After Kidney Transplantation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\",\"name\":\"Brendan Byrne\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"caption\":\"Brendan Byrne\"},\"description\":\"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Declared Initiation Of Eculizumab (Soliris\u00ae) Trial For Delayed Graft Function Prevention After Kidney Transplantation - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413","og_locale":"en_US","og_type":"article","og_title":"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Declared Initiation Of Eculizumab (Soliris\u00ae) Trial For Delayed Graft Function Prevention After Kidney Transplantation - Wall Street PR","og_description":"Boston, MA 08\/25\/2014 (wallstreetpr) \u2013 Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that it will be starting clinical trial of eculizumab (Soliris\u00ae) in order to evaluate [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-08-25T14:21:52+00:00","og_image":[{"width":259,"height":194,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Alexion-Pharmaceuticals-Inc.jpg","type":"image\/jpeg"}],"author":"Brendan Byrne","twitter_misc":{"Written by":"Brendan Byrne","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413"},"author":{"name":"Brendan Byrne","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511"},"headline":"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Declared Initiation Of Eculizumab (Soliris\u00ae) Trial For Delayed Graft Function Prevention After Kidney Transplantation","datePublished":"2014-08-25T14:21:52+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413"},"wordCount":349,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Alexion-Pharmaceuticals-Inc.jpg","keywords":["Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)","NASDAQ:ALXN"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413","url":"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413","name":"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Declared Initiation Of Eculizumab (Soliris\u00ae) Trial For Delayed Graft Function Prevention After Kidney Transplantation - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Alexion-Pharmaceuticals-Inc.jpg","datePublished":"2014-08-25T14:21:52+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Alexion-Pharmaceuticals-Inc.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/Alexion-Pharmaceuticals-Inc.jpg","width":259,"height":194},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/alexion-pharmaceuticals-inc-nasdaqalxn-declared-initiation-of-eculizumab-soliris-trial-for-delayed-graft-function-prevention-after-kidney-transplantation-29413#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Declared Initiation Of Eculizumab (Soliris\u00ae) Trial For Delayed Graft Function Prevention After Kidney Transplantation"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511","name":"Brendan Byrne","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","caption":"Brendan Byrne"},"description":"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/29413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=29413"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/29413\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/29414"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=29413"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=29413"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=29413"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=29413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}